14.72

0.81% -0.12

Eyepoint Inc (EYPT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$14.84

Aprire:

$14.8

Volume 24 ore:

1.64M

Relative Volume:

1.46

Capitalizzazione di mercato:

$1.23B

Reddito:

$7.62M

Utile/perdita netta:

$-271.60M

Rapporto P/E:

-4.2036

EPS:

-3.5018

Flusso di cassa netto:

$-271.54M

1 W Prestazione:

+5.29%

1M Prestazione:

+19.38%

6M Prestazione:

-9.30%

1 anno Prestazione:

+33.09%

Intervallo 1D:

$13.89

$14.80

Intervallo di 1 settimana:

$13.40

$14.99

Portata 52W:

$9.40

$19.11

Eyepoint Inc Stock (EYPT) Company Profile

Nome

Eyepoint Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

617-926-5000

Indirizzo

480 PLEASANT STREET, WATERTOWN, MA

Dipendente

214

Cinguettio

@eyepointpharma

Prossima data di guadagno

2026-08-05

Ultimi documenti SEC

EYPT's Discussions on Twitter

Compare EYPT vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EYPT Eyepoint Inc	14.72	1.23B	7.62M	-271.60M	-271.54M	-3.5018
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Eyepoint Inc Stock (EYPT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-17	Iniziato	RBC Capital Mkts	Outperform
2025-01-07	Iniziato	Citigroup	Buy
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-08-28	Iniziato	Jefferies	Buy
2024-01-22	Iniziato	JP Morgan	Overweight
2023-11-02	Iniziato	Mizuho	Buy
2023-04-21	Iniziato	Robert W. Baird	Outperform
2022-07-07	Iniziato	Chardan Capital Markets	Buy
2021-03-01	Iniziato	Cowen	Outperform
2021-01-28	Iniziato	Cantor Fitzgerald	Overweight
2020-04-06	Downgrade	B. Riley FBR	Buy → Neutral
2019-11-04	Ripresa	Laidlaw	Buy
2019-09-12	Iniziato	Guggenheim	Buy

Mostra tutto

Eyepoint Inc Borsa (EYPT) Ultime notizie

Jul 10, 2026

Does EyePoint’s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU‑Centric Investor Base? - simplywall.st

Jul 10, 2026

Jul 09, 2026

ETFs Investing in EyePoint, Inc. Stocks - TradingView

Jul 09, 2026

Jul 08, 2026

EyePoint Pharmaceuticals updates its strategy as retinal pipeline advances - ad-hoc-news.de

Jul 08, 2026

EyePoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight - Moomoo

Jul 08, 2026

EyePoint (EYPT) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr

Jul 08, 2026

Jul 07, 2026

Price to sales forward of EyePoint, Inc. – FWB:PV3B - TradingView

Jul 07, 2026

Here’s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks - Insider Monkey

Jul 07, 2026

Price-Driven Insight from (EYPT) for Rule-Based Strategy - Stock Traders Daily

Jul 07, 2026

Jul 06, 2026

EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901 - Ophthalmology Times Europe

Jul 06, 2026

Jul 05, 2026

Price to sales forward of EyePoint, Inc. – DUS:PV3B - TradingView

Jul 05, 2026

Price to earnings forward of EyePoint, Inc. – DUS:PV3B - TradingView

Jul 05, 2026

Guggenheim reiterates Buy on EyePoint stock, cites trial progress - Investing.com

Jul 05, 2026

Jul 03, 2026

EyePoint Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus

Jul 03, 2026

EyePoint Pharmaceuticals outlines long-term retina strategy as a specialty biotech - ad-hoc-news.de

Jul 03, 2026

EYPTEyePoint Inc Forecast, Target Price - Finviz

Jul 03, 2026

Jul 02, 2026

EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock By Investing.com - Investing.com South Africa

Jul 02, 2026

EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock - Investing.com

Jul 02, 2026

Form 4 Eyepoint Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026

EyePoint CMO sells 4,875 shares after option exercise | EYPT Insider Trading - Stock Titan

Jul 02, 2026

EYPT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Deceleration Risk - dars.gov.et

Jul 02, 2026

Jul 01, 2026

Spruce Street Capital LP's EyePoint Inc(EYPT) Holding History - GuruFocus

Jul 01, 2026

EYPT Rated Buy by Chardan Capital -- Price Target Raised to $65. - GuruFocus

Jul 01, 2026

Did Broad Russell Growth Index Additions Just Reframe EyePoint’s (EYPT) Small-Cap Biotech Profile? - Sahm

Jul 01, 2026

Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating - marketscreener.com

Jul 01, 2026

Huge - Moomoo

Jul 01, 2026

Chardan Capital Maintains EyePoint(EYPT.US) With Buy Rating, Raises Target Price to $65 - Moomoo

Jul 01, 2026

Jun 29, 2026

EyePoint, Inc.(NasdaqGM: EYPT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Pivotal Clinical Trial Readouts On The Horizon; Keeping An Eye On EyePoint? - RTTNews

Jun 29, 2026

EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could - The Motley Fool

Jun 29, 2026

EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

EyePoint, Inc.(NasdaqGM: EYPT) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Jun 26, 2026

Enterprise value to EBITDA forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView

Jun 26, 2026

EYPT Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesGAAP Earnings Report - dars.gov.et

Jun 26, 2026

(EYPT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Jun 26, 2026

Price to sales forward of EyePoint, Inc. – LS:A2QJRU - TradingView

Jun 26, 2026